Mohammad Nazmul Hasan Maziz

With an emphasis on formulation stability, safety, and clinical compatibility, the current study sought to create and assess stable parenteral emulsions for critical care medicine. Three batches of emulsions were made using pharmaceutical-grade lipids, emulsifiers, and isotonic agents, and the results were compared to control formulations. During a 90-day storage period at 4 °C, 25 °C, and 40 °C, physicochemical parameters such as droplet size, zeta potential, pH, and osmolarity were measured. While statistical analyses (ANOVA and Levene's Test) confirmed reproducibility and consistency across batches, sterility and endotoxin testing guaranteed microbial safety. According to the results, emulsions kept at 4 °C exhibited the best stability, whereas emulsions kept at higher temperatures experienced mild or rapid destabilization. Endotoxin levels were within pharmacopeial limits, and all batches remained sterile. The feasibility of creating stable and safe parenteral emulsions that can be administered intravenously to critically ill patients is highlighted in the study, along with the significance of appropriate storage conditions in maintaining formulation integrity.

Liposomal drug delivery methods are becoming popular nanocarriers for anticancer drugs because they make the drugs more available, target them more accurately, and lower their toxicity in the body. The goal of this project was to improve cancer treatment results by designing, formulating, and testing liposomal systems that include a model chemotherapeutic drug. We used the thin-film hydration approach to make three liposomal formulations (F1, F2, and F3) and then measured their particle size, zeta potential, polydispersity index, and entrapment efficiency. Studies of drug release in vitro showed that the drugs were released over time, with F3 exhibiting the largest cumulative release (89% at 24 hours). The MTT assay showed that F3 dramatically reduced the viability of MCF-7 cells (to 12% at 50 µg/mL), making it better than both other formulations and the free medication. One-way ANOVA statistical analysis showed that there were substantial differences (p

The technology and ability of 3D printing have transformed the sphere of personalized medicine, allowing manufacturing of the customized drug delivery to address diverse needs of a specific patient with regard to physiologic, pharmacokinetically, and therapeutically oriented preferences. This review generates a pharmaceutics-oriented view of the use of novel 3D printing technologies such as the Fused Deposition Modeling (FDM), Stereolithography (SLA), and inkjet printing in the development of personalized dosage forms comprising of oral tablets, implants, microneedles, and transdermal patches. Animal model experimental preclinical research, such as that in rabbits, rats, and mice, has proven the capability of the technologies to perform zero order release and controlled release of drugs, the capability to release multiple drugs using staggered kinetics, and to provide site-specific or minimally invasive delivery. The results support the benefits of structural flexibility, programmable release profiles, and improved patient adherence, especially in the case of complex conditions and important vulnerable groups of patients (pediatric and geriatric). But there are still some impediments on the way to clinical application, such as thermal instability of labile drugs, biocompatibility issues, poor reproducibility in device operation, a lack of standard regulatory frameworks, and insufficient long-term safety documentation. The review ends with a purpose of identifying the future research and development directions that include the necessity of the use of superior biocompatible materials, inherent hybrid printing methods and scalability in production, as well as interdisciplinary cooperation to enable clinical translation and redefine the future of personalized drug treatment.